Federal Register / Vol. 70, No. 232 / Monday, December 5, 2005 / Notices 72453 

carcinoma. The present technology 

relates to the isolation and 

characterization of a novel neutralizing 

chimpanzee monoclonal antibody to 

HBV. The antibody was identified 

through a combinatorial antibody 

library constructed from bone marrow 

cells of a chimpanzee experimentally 

infected with HBV. The selected 

monoclonal antibody has been shown to 

react equally well with wild-type HBV 

and the most common neutralization 

escape mutant variants. Therefore, this 

monoclonal antibody with high affinity 

and broad reactivity may have distinct 

advantages over other approaches to 

immunoprophylaxis and 

immunotherapy of chronic HBV 

infection, as most of the monoclonal 

antibodies currently in use are not 

sufficiently and broadly reactive to 

prevent the emergence of neutralization 

escape mutants of HBV. This technology 

describes such antibodies, fragments of 

such antibodies retaining hepatitis B 

virus-binding ability, fully human or 

humanized antibodies retaining 

hepatitis B virus-binding ability, and 

pharmaceutical compositions including 

such antibodies. This invention further 

describes isolated nucleic acids 

encoding the antibodies and host cells 

transformed with nucleic acids. In 

addition, this invention provides 

methods of employing these antibodies 

and nucleic acids in the in vitro and in 

vivo diagnosis, prevention and therapy 

of HBV diseases. 

In addition to licensing, the 

technology is available for further 

development through collaborative 

research opportunities with the 

inventors. 

Polypeptide Multimers Having 

Antiviral Activity 

Carol Weiss et al. (FDA) 

PCT Application No. PCT/US03/25295 

filed 14 Aug 2003, which published 

as WO 2005/018666 on 03 Mar 2005 

(HHS Reference No. E–155–2003/0- 

PCT–01) 

Licensing Contact: Susan Ano; 301/435–

5515; anos@mail.nih.gov. 

The technology describes polypeptide 

multimers that have antiviral and 

immunogenic activity against HIV. 

These multimers consist of at least one 

monomer of the highly conserved N and 

C heptad regions of gp41 in a ratio of at 

least 2:1 N to C heptad, with the N and 

C heptads being connected by linkers. 

The monomer forms homodimers and 

homotrimers in solution and mimic 

fusion intermediate structure. Further, 

the technology also describes a method 

of raising a broadly neutralizing 

antibody response to HIV by 

administering the polypeptide 

multimers mentioned above. Thus, 

these polypeptide multimers may be 

used as antiviral (anti-HIV) agents. 

Because the structure of these 

polypeptide multimers mimics the gp41 

fusion intermediate, they can also be 

used to identify compounds that may 

inhibit the fusion process. 

In addition to licensing, the 

technology is available for further 

development through collaborative 

research opportunities with the 

inventors. 

Dated: November 15, 2005. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E5–6803 Filed 12–2–05; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the meeting of the 

Advisory Committee to the Director, 

National Institutes of Health (NIH). 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

A portion of the meeting will be 

closed to the public in accordance with 

the provisions set forth in sections 

552b(c)(6) and 552b(c)(9)(B), Title 5 

U.S.C., as amended, because the 

disclosure of which would constitute a 

clearly unwarranted invasion of 

personal privacy and the premature 

disclosure of information and the 

discussions would likely to significantly 

frustrate implementation of the 

program. 

Name of Committee: Advisory Committee 

to the Director, NIH. 

Date: December 1–2, 2005. 

Closed: December 1, 2005, 8:30 a.m. to 9:45 

a.m. 

Agenda: Office of Portfolio Analysis and 

Strategic Initiatives (OPASI). 

Place: National Institutes of Health, 9000 

Rockville Pike, Building 31, Conference 

Room 6, Bethesda, MD 20892. 

Open: December 1, 2005, 10 a.m. to 4:30 

p.m. 

Agenda: Among the topics proposed for 

discussion are: (1) NIH Director’s Report; (2) 

Clinical and Translational Science Awards; 

(3) NIH Director’s Council of Public 

Representatives Liaison Report; and (4) 

update on NIH Neurosciences Blueprint. 

Place: National Institutes of Health, 9000 

Rockville Pike, Building 31, Conference 

Room 6, Bethesda, MD 20892. 

Open: December 2, 2005, 9 a.m. to 12 p.m. 

Agenda: Among the topics proposed for 

discussion are: (1) Office of Portfolio 

Analysis and Strategic Initiatives (OPASI); (2) 

Public Access Update; and (3) Workgroup 

Report on Outside Awards for NIH 

Employees. 

Place: National Institutes of Health, 9000 

Rockville Pike, Building 31, Conference 

Room 6, Bethesda, MD 20892. 

Contact Person: Shelly Pollard, ACD 

Coordinator, Office of Communications and 

Public Liaison, Office of the Director, 

National Institutes of Health, 31 Center Drive, 

Building 31, Room 5B64, Bethesda, MD 

20892, Phone: (301) 496–0959, 

pollards@mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

into the building by non-government 

employees. Persons without a government 

I.D. will need to show a photo I.D. and signin at the security desk upon entering the 

building. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.nih.gov/about/director/acd.htm where 

an agenda and any additional information for 

the meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.22, Clinical Research 

Loan Repayment Program for Individuals 

from Disadvantaged Backgrounds; 93.232, 

Loan Repayment Program for Research 

Generally; 93.39, Academic Research 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiency Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS) 

Dated: November 22, 2005. 

Nancy Middendorf, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–23590 Filed 12–2–05; 8:45 am] 

BILLING CODE 4140–01–M